Deudomperidone (CIN-102)
Idiopathic Gastroparesis
Key Facts
About CinDome Pharma
CinDome Pharma is a specialized biotech advancing deudomperidone (CIN-102), a prokinetic and antiemetic designed to improve upon the safety profile of existing gastroparesis treatments. The company leverages the hub-and-spoke operational model of its parent, CinRx, for efficient clinical development. Its strategy targets the substantial market of 12-16 million symptomatic patients in the U.S. alone, where current options are limited to short-term use or carry significant safety warnings.
View full company profileAbout CinDome Pharma
CinDome Pharma is a specialized biotech advancing deudomperidone (CIN-102), a prokinetic and antiemetic designed to improve upon the safety profile of existing gastroparesis treatments. The company leverages the hub-and-spoke operational model of its parent, CinRx, for efficient clinical development. Its strategy targets the substantial market of 12-16 million symptomatic patients in the U.S. alone, where current options are limited to short-term use or carry significant safety warnings.
View full company profile